The paper is an expert meeting report rather than a new clinical trial. It followed a meeting organised by GALENOS and the European College of Neuropsychopharmacology, which brought together researchers, clinicians, industry partners and people with lived experience to identify priorities for future research into anhedonia. Lead co-author Brenda Penninx said anhedonia can mean enjoying normally pleasant activities less, anticipating them less or feeling less motivated to make an effort for them. “This distinction is precisely what matters,” Penninx said, because anhedonia is likely to involve different processes surrounding reward and motivation rather than a single phenomenon with one cause.

The meeting was prompted by recent results from the GALENOS living systematic review of drugs that increase dopamine activity. These treatments produced some improvements in anhedonia symptoms, but the effects were relatively small. The review also found that some antidepressants acting through non-dopaminergic mechanisms were associated with bigger reductions in anhedonia than pro-dopaminergic drugs. Lead co-author Andrea Cipriani said the neurobiology of anhedonia in depression likely involves systems that include, but are not limited to, dopaminergic pathways. The report presents these systematic-review observations as the foundation for a research agenda; it does not establish that any medication should be prescribed for anhedonia or that a non-dopaminergic antidepressant is clinically superior for its treatment.

Researchers propose treating anhedonia as an umbrella encompassing several related but distinguishable processes, including reward anticipation, motivation, reward learning and the experience of pleasure itself. Different components may involve different biological systems, among them dopaminergic, glutamatergic, opioid, inflammatory and metabolic pathways. The report therefore supports investigating a broader network of mechanisms rather than assuming that one biological pathway explains every aspect of the symptom. This focus is relevant because anhedonia occurs in depression, schizophrenia, bipolar disorder, Parkinson’s disease and other conditions, and is associated with poorer quality of life, impaired daily functioning and poorer treatment outcomes. The scope of the report is a research strategy informed by evidence and expert discussion, not a comprehensive clinical guideline or proof that the proposed model accounts for every form of anhedonia.

To accelerate progress, the report calls for more precise definitions and measurement tools, greater use of biological markers, and clinical trials that treat anhedonia as a primary outcome rather than only a secondary symptom of depression. The authors also call for studies spanning different disorders and stages of life to clarify how anhedonia develops and responds to treatment. These are proposed priorities and methods, not established therapeutic benefits. By separating the processes that contribute to anhedonia and measuring them more directly, the authors argue, researchers may improve the targeting of future studies and potentially support more effective, personalised approaches. Whether that broader understanding yields clinically useful treatments remains an open question that requires further research and appropriately designed trials.

Subject of Research: Research agenda for anhedonia assessment and treatment across depression and other disorders

Article Title: Dopamine-targeting treatments show only modest benefits for anhedonia, prompting call for new research approaches

Article References: Dopamine-targeting treatments show only modest benefits for anhedonia, prompting call for new research approaches. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: anhedonia, dopamine, depression, antidepressants, reward processing, GALENOS, systematic review, mental health research, clinical trials, precision psychiatry, Dopamine-targeting, treatments